Reviva Pharmaceuticals Holdings, Inc.
RVPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001742927
No open-market purchases or sales by Reviva Pharmaceuticals Holdings, Inc. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $3.67K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Reviva Pharmaceuticals Holdings, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q4 2022
- Shares held
- 1.38M
- +72.1K (+5.5%) vs. Q4 2022
- Total value
- $5.76M
- +$222.0K (+4.0%) vs. Q4 2022
- New holders
- 4
- 4 more added
- Sold out
- 5
- 9 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $3.67K |
| Q1 2026 | 35 | $2.13M |
| Q4 2025 | 48 | $3.17M |
| Q3 2025 | 42 | $3.52M |
| Q2 2025 | 46 | $5.44M |
| Q1 2025 | 49 | $6.95M |
| Q4 2024 | 42 | $14.0M |
| Q3 2024 | 33 | $14.3M |
| Q2 2024 | 31 | $8.75M |
| Q1 2024 | 28 | $21.0M |
| Q4 2023 | 36 | $27.1M |
| Q3 2023 | 24 | $13.0M |
| Q2 2023 | 23 | $15.5M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 23 | $5.54M |
| Q3 2022 | 19 | $1.65M |
| Q2 2022 | 13 | $2.05M |
| Q1 2022 | 16 | $4.68M |
| Q4 2021 | 14 | $7.54M |
| Q3 2021 | 12 | $10.5M |
| Q2 2021 | 12 | $12.8M |
| Q1 2021 | 8 | $3.37M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Reviva Pharmaceuticals Holdings, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 573,770 | $2.40M | 0.00% | +107,353+23.0% | Added |
| Geode Capital Management, LLC | 145,430 | $609.4K | 0.00% | 00.0% | Unchanged |
| EMC Capital Management | 123,915 | $517.0K | 0.43% | 00.0% | Unchanged |
| Colony Group LLC | 93,000 | $390.0K | 0.01% | +93,000 | New |
| BlackRock Inc. | 84,954 | $356.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 73,108 | $306.3K | 0.00% | −18,422−20.1% | Reduced |
| Tang Capital Management LLC | 53,200 | $222.9K | 0.03% | +29,075+120.5% | Added |
| State Street Corp | 44,400 | $186.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 38,435 | $161.0K | 0.00% | +38,435 | New |
| Sabby Management, LLC | 28,610 | $119.9K | 0.45% | −5,890−17.1% | Reduced |
| Northern Trust Corp | 27,115 | $113.6K | 0.00% | −4,138−13.2% | Reduced |
| Renaissance Technologies LLC | 19,124 | $80.0K | 0.00% | −1,176−5.8% | Reduced |
| Two Sigma Investments, LP | 16,400 | $68.7K | 0.00% | −30,635−65.1% | Reduced |
| Bank of New York Mellon Corp | 15,047 | $63.0K | 0.00% | +511+3.5% | Added |
| Goldman Sachs Group Inc | 12,236 | $51.3K | 0.00% | −16,986−58.1% | Reduced |
| Northwestern Mutual Wealth Management Co | 9,299 | $39.0K | 0.00% | 00.0% | Unchanged |
| Belvedere Trading LLC | 6,359 | $26.6K | 0.01% | +6,359 | New |
| Wolverine Asset Management LLC | 6,104 | $25.6K | 0.00% | −710−10.4% | Reduced |
| Citadel Advisors LLC | 3,526 | $14.8K | 0.00% | +3,526 | New |
| Tower Research Capital LLC (TRC) | 1,519 | $6.00K | 0.00% | −8,518−84.9% | Reduced |
| Wells Fargo & Company | 110 | $461 | 0.00% | +1+0.9% | Added |
| Bank of America Corp | 1 | $4 | 0.00% | −33−97.1% | Reduced |
| XTX Topco Ltd | 0 | $0 | 0.00% | −58,475−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −38,600−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −12,232−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −10,303−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −12−100.0% | Sold out |